What's behind Hims & Hers's latest stock pullback?

Traders Union
All News
Stocks
Hims & hers slides 3.27% today

Highlights

Hims & Hers Health is expected to announce third quarter 2026 earnings of $0.0566 per share on revenue of $892.88 million.
Active securities class action lawsuits carry a key filing deadline of November 2, 2026, adding legal uncertainty.
Shares of Hims & Hers trade below key moving averages with oversold technical signals and an expected five-day range of $25.07 to $28.89.

Analyst expectations and legal pressures shape market sentiment ahead of results

Hims & Hers Health Inc. is scheduled to release its third quarter 2026 earnings results after the market closes on November 9, 2026. Analysts expect the company to report earnings of $0.0566 per share and revenue of $892.88 million for the quarter. Several law firms have issued press releases concerning ongoing securities class action lawsuits, with a key filing deadline of November 2, 2026. The company last reported a negative net margin of 5.51% and a negative return on equity of 6.51%.

Anton Kharitonov, expert at Traders Union, notes that Hims & Hers faces strong selling momentum with the stock under all key moving averages. He highlights the negative net margin and return on equity as ongoing fundamental weaknesses. Persistent lawsuits and the looming earnings report keep investor sentiment fragile. Technically, multiple indicators point to oversold conditions, but he sees little sign of immediate reversal. "With downside pressure likely to persist, I advise caution until stability above $27.03 can be confirmed," Kharitonov says.

Viktoras Karapetjanc, expert at Traders Union, believes the longer-term bullish structure remains intact despite recent volatility. He points out that the company’s upcoming earnings and large revenue base suggest forward momentum, while the earlier rally keeps the 50-day average above the 200-day. Constructive news flow offers the potential for renewed investor interest. "Should HIMS reclaim $27.03, further growth toward $28.89 remains a distinct opportunity for traders," Karapetjanc asserts.

Sholanke Dele, market strategist, sees heightened risk for Hims & Hers following its drop and ongoing legal concerns. Broader market caution and negative headlines may amplify outflows. Dele warns that breaking below $26.69 could lead to sharper downside. "For now, I see little reason to expect a quick rebound given the prevailing sentiment and legal overhang," Dele states.

Technical weakness as oversold signals intensify amid stalled momentum

Hims & Hers is currently trading below its 20-day ($28.94), 50-day ($29.04), and 200-day ($27.03) moving averages, indicating pressure from sellers across all time frames. Immediate resistance stands at $27.03, while near-term support is marked by the recent weekly low of $26.69. Longer-term trend structure remains bullish since the 50-day average is above the 200-day average. Momentum signals are negative: the MACD shows a "Sell" reading, the ADX at 11.97 reflects a weak trend, and the RSI at 44.96 points to persistent downside. Both the Stochastic RSI (12.53) and CCI (-112.01) show deep oversold conditions. Bull/Bear Power is slightly positive at 0.09, suggesting intraday buyers have a small edge, though this is tempered by oversold signals. The stock opened with a $0.28 upside gap but now trades near the daily low as momentum has declined along with price action. Volatility stands at 4.05%, with overall tone pressured after the open.

Previously it was reported that Hims & Hers faced mounting downside pressure due to ongoing securities litigation and technical weakness. The current analysis reinforces this outlook by highlighting persistent bearish momentum across all major indicators, with a critical risk that a breakdown below $26.69 could accelerate losses toward $25.07 in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.